Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab). This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results